These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 32700072)
1. The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072 [TBL] [Abstract][Full Text] [Related]
2. New drugs creating new challenges in acute myeloid leukemia. Tiong IS; Wei AH Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214 [TBL] [Abstract][Full Text] [Related]
3. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602 [TBL] [Abstract][Full Text] [Related]
4. What to use to treat AML: the role of emerging therapies. Thol F Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359 [TBL] [Abstract][Full Text] [Related]
5. Venetoclax-based therapies for acute myeloid leukemia. Guerra VA; DiNardo C; Konopleva M Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996 [TBL] [Abstract][Full Text] [Related]
6. Current status and research directions in acute myeloid leukemia. Kantarjian H; Borthakur G; Daver N; DiNardo CD; Issa G; Jabbour E; Kadia T; Sasaki K; Short NJ; Yilmaz M; Ravandi F Blood Cancer J; 2024 Sep; 14(1):163. PubMed ID: 39300079 [TBL] [Abstract][Full Text] [Related]
7. [Incorporation of novel agents into the treatment for acute myeloid leukemia]. Yamauchi T Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501 [TBL] [Abstract][Full Text] [Related]
9. Incorporating newer agents in the treatment of acute myeloid leukemia. Raj RV; Abedin SM; Atallah E Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522 [TBL] [Abstract][Full Text] [Related]
10. Progress and predictions: AML in 2018. Rowe JM Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743 [TBL] [Abstract][Full Text] [Related]
11. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Wei AH; Tiong IS Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180 [TBL] [Abstract][Full Text] [Related]
12. Will new agents impact survival in AML? Rowe JM Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986 [TBL] [Abstract][Full Text] [Related]
13. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Bewersdorf JP; Stahl M; Zeidan AM Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518 [TBL] [Abstract][Full Text] [Related]
14. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? Stone RM Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201 [TBL] [Abstract][Full Text] [Related]
15. Novel Agents for Acute Myeloid Leukemia. Luppi M; Fabbiano F; Visani G; Martinelli G; Venditti A Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30423907 [TBL] [Abstract][Full Text] [Related]
16. Safety considerations for drugs newly approved for treating acute myeloid leukemia. Gołos A; Góra-Tybor J; Robak T Expert Opin Drug Saf; 2024 Nov; 23(11):1393-1404. PubMed ID: 39364854 [TBL] [Abstract][Full Text] [Related]
17. [Novel Strategies to Treat Acute Myeloid Leukemia]. Gediga MHE; Middeke JM; Ruhnke L Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117 [TBL] [Abstract][Full Text] [Related]
18. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. Bohl SR; Bullinger L; Rücker FG Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543 [TBL] [Abstract][Full Text] [Related]
19. Single-agent and combination biologics in acute myeloid leukemia. Richard-Carpentier G; DiNardo CD Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888 [TBL] [Abstract][Full Text] [Related]